HOME >> BIOLOGY >> NEWS
FDA approves Raptiva (efalizumab) for chronic moderate-to-severe plaque psoriasis

South San Francisco, CA, and Berkeley, CA Genentech, Inc. (NYSE: DNA) and XOMA Ltd. (Nasdaq: XOMA) announced today that RAPTIVA (efalizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. RAPTIVA is the first biologic therapy that is designed to provide continuous control of chronic moderate-to-severe plaque psoriasis and can be self-administered by patients as a single, once-weekly, subcutaneous injection.

"Today's FDA approval of RAPTIVA underscores our commitment to delivering innovative therapies to patients with unmet medical needs," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. "Through our collaboration with XOMA, the clinical trial investigators and most importantly, the over 2,700 patients who participated in our clinical trials, we are proud to offer a new therapeutic option to help patients manage this chronic disease."

"RAPTIVA represents XOMA's first product approval and is the culmination of a highly successful collaboration with Genentech," said John L. Castello, XOMA's chairman, president and chief executive officer. "The companies have worked together on a robust clinical program that has demonstrated the safety and efficacy of RAPTIVA. We view RAPTIVA now being available to
patients as a worthy testament to the confidence of our shareholders and the hard work and support of both companies'
employees."

"I've been treating psoriasis for over 15 years and have always been frustrated by the limited options available to treat patients with this chronic disease. Safety limitations of traditional therapies have made it difficult to offer patients continuous relief," said Craig Leonardi, M.D., clinical associate professor of dermatology of Saint Louis University, St. Louis, Mo. and a RAPTIVA clinical investigator. "RAPTIVA
'"/>

Contact: Emmy Tsui
emmy.tsui@ketchum.com
585-256-0195
Ketchum
27-Oct-2003


Page: 1 2 3 4 5 6

Related biology news :

1. FDA approves VYTORIN, first and only to powerfully reduce LDL cholesterol through dual inhibition
2. European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer
3. FDA approves Abbotts Biaxin XL (clarithromycin extended-release tablet)for community-acquired pneumonia
4. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia
5. DFG approves 14 new research training units
6. National Science Board approves five new NSF Science and Technology Centers
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Results from open-label Raptiva study suggest continued benefit with long-term treatment
9. Genes appear to play a role in development of chronic obstructive pulmonary disease
10. New research supports theory that indirect transmission of chronic wasting disease
11. Animal studies show promise treating severe chronic pain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2018)... ... December 04, 2018 , ... Biolytic Lab Performance Inc. ... 192c, built on Biolytic’s Molecule Synthesis Platform. , Now restructured with all ... the world’s fastest in oligonucleotide synthesis, the 192c incorporates a multitude of enhancements ...
(Date:11/29/2018)... ... November 29, 2018 , ... Tosoh Bioscience LLC ... of acquiring full ownership. The transaction was approved by the Board of Directors ... 2018. “We are extremely pleased to team up with Tosoh Bioscience to offer ...
(Date:11/27/2018)... ... November 26, 2018 , ... PulseEd™ uses researched technology, published in the ... stimulate blood flow to the penis. Regular and unimpeded blood flow to the blood ... good erectile function. The recorded results of SWT (sound wave therapy), indicated that almost ...
Breaking Biology News(10 mins):
(Date:11/13/2018)... , ... November 13, 2018 , ... ... Aqua® Research Water Life Science® in Grants Pass, Oregon believes in the power ... Bio-Logic Aqua® Research Water Life Science® sponsors the Power of Water® on talk ...
(Date:11/9/2018)... ... 08, 2018 , ... IC System, one of the largest ... increasing recovery rates by creating a comprehensive contact strategy for each consumer. ... NLP Logix, a Jacksonville, Florida-based AI solutions company, and leveraged the decades of ...
(Date:11/7/2018)... ... , ... Diversified Technologies, Inc. (DTI) has installed a PEF (Pulsed ... Technology and Innovation at ASU. Funded by a USDA NIFA SBIR, the purpose of ... and predator control applications. , Algae ponds get up to 50% consumed by predators ...
(Date:11/5/2018)... (PRWEB) , ... November 05, 2018 , ... ... and telemedicine company backed by Siemens Healthineers and several healthcare VC firms announces ... radiology solution and making a history by purchasing tokens and obtaining its first ...
Breaking Biology Technology:
Cached News: